RCUS LONGI expect a first touch bounce of the montly $11.66 level. I pulled this fib off the move to the all time high and I will be targeting the two boxes above. My fibs are pulled from the move to the all time high.
RCUS trade ideas
RCUS 1M 7.4% Increase and then 77% DeclineArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
RCUS:Bullish continuation!Arcus Biosciences
Short Term - We look to Buy at 27.75 (stop at 25.94)
Daily signals are bullish. A weaker opening is expected to challenge bullish resolve. Prices expected to stall near trend line support. Dip buying offers good risk/reward. Further upside is expected although we prefer to buy into dips close to the 27.00 level.
Our profit targets will be 32.77 and 34.00
Resistance: 32.80 / 40.00 / 47.00
Support: 27.00 / 17.50
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
RCUSThis BioScience company has many products in the testing phases through to the FDA approvals. The stock has also missed earnings multiple times in the past and that is the majority reason why it is currently failing. keep a watch on this to see if it hits new lows and can be a great buy if one of the FDA approvals approaches and the company could see significant increases in revenue and earnings causing the price to go up
RCUS - Long Setup Phase 2 data expected 2Q 2021 based on BioPharm catalyst website. Gilead have been buying as well as another insider. Watch for a break of 36.13. Stop signal 26.44. Momentum target.
Interesting Oppty...Analyst targets are pretty high and carries Zacs #1 rating. A breakout will lead it higher.
finance.yahoo.com
RCUS 50+% Potential Gains Friday, January 15-17RCUS releases phase one clinical trial data for a drug they are developing to treat pancreatic cancer on Friday, January 15-17. Look to buy about a week in advance.
RCUS 50% retrace/50/200 EMA supportRCUS has reacted higher after bouncing from a confluence of support:
1) 200 EMA
2) 50% retracement
3) VWAP from all time low
*You can see how the 200 EMA and VWAP from all time low previously acted as the floor back in March
-Now supported strongly by 50 EMA, RCUS closed above the 50 EMA every day this week, and 7 of the last 8 days, with the exception appearing to be a 'gap fill.'
-I am looking for RCUS to continue to find support on the 50 EMA or the VWAP from the 200 EMA bounce
-Close above the $25.5 level is the buy trigger, which will also complete an inverse H&S pattern which has been forming for the last month
Arcus Biosciences on hot watch for breakout. Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Overreaction, strong support and gap above = Long $RCUS1. tremendous drop in the first hour on Friday with a modest rebound, showing the initial overreaction had passed.
2. close above the Strong bottom support line
3. Friday's slump left a big Gap above!
3. there are 2 resistance line near above. Once opening above the first resistance line which is 9.06, the space going up is huge!
Stop loss price can be set at the support line below.
Ratio of Profit and Loss is 3.88.
Potential profit is about 11%.
Worth giving it a shot!
RCUS Insider trading + chart looks to be reversingThe risk reward looks... rewarding.
Tread your path
Recent IPO RCUS setting up nicely for a breakout. On watch.Initiated a small position under $16 with a stop at $15.12
